
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
If you’ve been around drug development for a while, the rise of GLP-1 therapies might sound familiar to you: a breakthrough emerges after years of hard work in the clinic. A leader captures the market. Billions are made. Copycats follow, hoping for a slice …